ADVENTRX Pharmaceuticals, Inc.

Biopharma company initiates patient treatment in colorectal cancer trial

Published in Pharma Law Weekly, June 28th, 2005

ADVENTRX Pharmaceuticals, Inc., (ANX) announced it has initiated patient treatment in its international, 300-patient phase IIb clinical trial to evaluate the safety and efficacy of the company's lead drug candidate, CoFactor, used in combination with 5-fluorouracil (5-FU) for the treatment of metastatic colorectal cancer.

The company also announced that it has received the necessary regulatory and ethics approvals from the individual countries' regulatory agencies to initiate the trial in the United Kingdom, Germany, Romania, Serbia and India. These individual country approvals are required in addition to clearance from the Medicines and Healthcare Products Regulatory...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Pharma Law Weekly

Source: Pharma Law Weekly (2005-06-28)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry